World's first oral microbiome-based nanomedicine to supercharge anti-cancer immunity Engineered a DHB prodrug-based oral nano-emulsion with enhanced bioavailability, dramatically improving the efficacy of immune checkpoint blockade therapy. Moon from the University of Michigan—has successfully developed the world’s first oral, microbiome-based nanomedicine. By leveraging natural metabolites produced by gut bacteria, the new drug significantly enhances the ability of immune cells to attack cancer cells. The gut microbial metabolite DHB promotes the formation of antigen-specific, stem-like CD8+ T cells by suppressing glycolysis and modulating the Akt-mTORC1-Myc pathway. This oral nanomedicine drastically extends the time the drug stays in the bloodstream, boosting its overall absorption rate (bioavailability) by 14.3 times.